Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From IncellDx, Inc.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
The October introduction of Gen-Probe’s new cervical cancer screening test may up the stakes in the battle over market share in testing for HPV, the cause of cervical cancer. That’s good news for several companies. One is OncoHealth, which is developing a low-cost protein-based test for direct measurement of E6E7, two important oncoproteins associated with HPV progression to cancer that are a part of Gen-Probe’s new test panel.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing